RAF265 (CHIR-265)

Catalog No. A10773

RAF265 (CHIR-265)是一种口服，高度选择性的RAF和VEGFR激酶抑制剂，可控制或正常化VEGFR-2，同时抑制B-raf和c-Raf突变以预防癌症。

Technical details

Catalog Num	A10773
M. Wt	518.4
Formula	C24H16F6N6O
Purity	>98%
Storage	at -20°C 3 years Powder
CAS No.	927880-90-8
Synonyms
SMILES	CN1C2=C(C=C(C=C2)OC3=CC(=NC=C3)C4=NC=C(N4)C(F)(F)F)N=C1NC5=CC=C(C=C5)C(F)(F)F

Biological Activity

RAF265 (CHIR-265)是一种口服，高度选择性的RAF和VEGFR激酶抑制剂，可控制或正常化VEGFR-2，同时抑制B-raf和c-Raf突变以预防癌症。

Targets

VEGFR2 (Cell-free assay)	B-Raf (Cell-free assay)
30 nM(EC50)	3 nM-60 nM

Solubility *

In vitro (25°C)	DMSO	85 mg/mL (163.96 mM)
	Water	Insoluble
	Ethanol	28 mg/mL (54.01 mM)
In vivo	30% PEG400+0.5% Tween80+5% propylene glycol	28 mg/mL
* <1 mg/ml means slightly soluble or insoluble. * Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Preparing Stock Solutions

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
0.1 mM	19.29 mL	96.45 mL	192.9 mL
0.5 mM	3.86 mL	19.29 mL	38.58 mL
1 mM	1.93 mL	9.65 mL	19.29 mL
5 mM	0.39 mL	1.93 mL	3.86 mL

*The above data is based on the productmolecular weight 518.4 . Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.